Faculty

Back to Index
Paul Stephen Aisen, MD
Professor of Neurology
Director, Alzheimer's Therapeutic Research Institute
Neurology
ATR 10182 Telesis Court Health Sciences Campus San Diego

Overview

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

Publications

Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 Aug 26; 48:172-181. View in: PubMed

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 Jun 1; 73(6):721-32. View in: PubMed

Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016 May 31; 86(22):2071-6. View in: PubMed

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 May 17; 86(20):1887-96. View in: PubMed

Thomas RG, Albert M, Petersen RC, Aisen PS. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimers Dement. 2016 May; 12(5):598-603. View in: PubMed

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. View in: PubMed

Rentz DM, Dekhtyar M, Sherman J, Burnham S, Blacker D, Aghjayan SL, Papp KV, Amariglio RE, Schembri A, Chenhall T, Maruff P, Aisen P, Hyman BT, Sperling RA. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. View in: PubMed

Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. View in: PubMed

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016; 8:25. View in: PubMed

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan; 12(1):56-61. View in: PubMed

Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016; 9 Suppl 1:30. View in: PubMed

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016; 8:39. View in: PubMed

Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-29. View in: PubMed

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91. View in: PubMed

Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW. The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. View in: PubMed

Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015 Oct; 138(Pt 10):3076-88. View in: PubMed

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. View in: PubMed

Rueda AD, Lau KM, Saito N, Harvey D, Risacher SL, Aisen PS, Petersen RC, Saykin AJ, Farias ST. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement. 2015 Sep; 11(9):1080-9. View in: PubMed

Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement. 2015 Sep; 11(9):1069-79. View in: PubMed

Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep; 14(9):926-44. View in: PubMed

Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015 Jul 9; 47(1):205-14. View in: PubMed

Beckett LA, Donohue MC, Wang C, Aisen P, Harvey DJ, Saito N. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015 Jul; 11(7):823-31. View in: PubMed

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015 Jul; 11(7):865-84. View in: PubMed

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement. 2015 Jul; 11(7):772-91. View in: PubMed

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-e120. View in: PubMed

Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. View in: PubMed

Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May 1; 72(5):554-60. View in: PubMed

Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's disease cooperative study cognitive function instrument. JAMA Neurol. 2015 Apr 1; 72(4):446-54. View in: PubMed

Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. View in: PubMed

Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta KL, Farrer LA. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015 Mar; 77(3):547-52. View in: PubMed

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. View in: PubMed

Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. View in: PubMed

Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. View in: PubMed

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. View in: PubMed

Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015 Jan 1; 43(3):949-55. View in: PubMed

Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR, Aisen PS, Shaw LM, Trojanowski JQ, Weiner MW. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. 2015 Jan; 36(1):273-82. View in: PubMed

Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR, Weiner MW, Dartigues JF, Aisen PS. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. View in: PubMed

Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70. View in: PubMed

Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15; 83(3):253-60. View in: PubMed

Weiner MW, Veitch DP, Hayes J, Neylan T, Grafman J, Aisen PS, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Shaw LM, Saykin AJ, Green RC, Harvey D, Toga AW, Friedl KE, Pacifico A, Sheline Y, Yaffe K, Mohlenoff B. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. View in: PubMed

Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's disease cooperative study prevention instrument project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. View in: PubMed

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology. 2014 Apr 29; 82(17):1536-42. View in: PubMed

Aisen PS. Serum brain-derived neurotrophic factor and the risk for dementia. JAMA. 2014 Apr 23-30; 311(16):1684-5. View in: PubMed

Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. View in: PubMed

Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. View in: PubMed

Doody RS, Farlow M, Aisen PS. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 Apr 10; 370(15):1460. View in: PubMed

Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. View in: PubMed

Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. View in: PubMed

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21. View in: PubMed

Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014; 14:12. View in: PubMed

Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA, Mathis CA, Shaw LM, Trojanowski JQ, Soares H, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Association of plasma and cortical amyloid beta is modulated by APOE e4 status. Alzheimers Dement. 2014 Jan; 10(1):e9-e18. View in: PubMed

Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. View in: PubMed

Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Oct 24; 369(17):1661. View in: PubMed

Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen PS, Jagust WJ, Weiner MW, Jack CR. Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. View in: PubMed

Sano M, Egelko S, Donohue M, Ferris S, Kaye J, Hayes TL, Mundt JC, Sun CK, Paparello S, Aisen PS. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. View in: PubMed

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep; 9(5):e111-94. View in: PubMed

Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Lee JY, Jack CR, Aisen PS, Petersen RC, Weiner MW. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. View in: PubMed

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. View in: PubMed

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. View in: PubMed

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. View in: PubMed

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. View in: PubMed

Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul; 27(4):391-401. View in: PubMed

Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. View in: PubMed

Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013 Apr; 12(4):324. View in: PubMed

Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Aisen PS. Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc. 2013 Mar; 61(3):396-402. View in: PubMed

Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. View in: PubMed

Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. JAMA Neurol. 2013 Feb; 70(2):270-1. View in: PubMed

Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013 Jan 15; 80(3):282-8. View in: PubMed

Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013; 8(9):e74062. View in: PubMed

Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. View in: PubMed

Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269. View in: PubMed

Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, Foroud TM, Mukherjee S, Crane PK, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012 Dec; 6(4):634-48. View in: PubMed

Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct; 72(4):578-86. View in: PubMed

Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 1; 2(10):975-984. View in: PubMed

Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 Sep; 11(9):655-6. View in: PubMed

Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N, Weiner MW. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004. View in: PubMed

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30; 367(9):795-804. View in: PubMed

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 Jul; 69(7):836-41. View in: PubMed

Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Knopman DS. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. View in: PubMed

Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. View in: PubMed

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. View in: PubMed

Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Knopman DS. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. View in: PubMed

Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm. 2012 Jul; 119(7):843-50. View in: PubMed

Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM. Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun; 69(6):709-13. View in: PubMed

Reiman EM, Brinton RD, Katz R, Petersen RC, Negash S, Mungas D, Aisen PS. Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. View in: PubMed

Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR, Weiner MW. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012 May; 33(5):845-55. View in: PubMed

Mackin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. View in: PubMed

Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3985-90. View in: PubMed

Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar; 69(3):368-72. View in: PubMed

Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. View in: PubMed

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. View in: PubMed

Tractenberg RE, Yumoto F, Aisen PS, Kaye JA, Mislevy RJ. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". PLoS One. 2012; 7(2):e30019. View in: PubMed

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. View in: PubMed

Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol. 2011 Dec; 95(4):594-600. View in: PubMed

Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011 Dec; 68(12):1526-35. View in: PubMed

Aisen PS. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. View in: PubMed

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. View in: PubMed

Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011 Nov 30; 3(111):111cm33. View in: PubMed

Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. View in: PubMed

Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. View in: PubMed

Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66. View in: PubMed

Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM. Factors affecting Aß plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011 Oct; 122(4):401-13. View in: PubMed

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW. Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011 Sep; 7(5):514-20. View in: PubMed

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. View in: PubMed

Vellas B, Pesce A, Robert PH, Aisen PS, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. View in: PubMed

Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. View in: PubMed

Vellas B, Pesce A, Robert PH, Aisen PS, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. View in: PubMed

Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain. 2011 May; 134(Pt 5):1479-92. View in: PubMed

Aisen PS. Commentary on "Biomarkers in Alzheimer's disease drug development. " Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. View in: PubMed

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):280-92. View in: PubMed

Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. View in: PubMed

Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR. Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid. Alzheimers Dement. 2011 Mar; 7(2):133-41. View in: PubMed

Donohue MC, Gamst AC, Aisen PS. Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. View in: PubMed

Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S, Weiner MW, Carrillo MC, Bain LJ. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar; 7(2):127-32. View in: PubMed

Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb; 7(1):102-11. View in: PubMed

Aisen PS. Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011; 9:101. View in: PubMed

Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011; 3(1):1. View in: PubMed

Rammouz G, Lecanu L, Aisen P, Papadopoulos V. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:5-16. View in: PubMed

Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011; 6(1):e16259. View in: PubMed

Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011; 6(1):e16259. View in: PubMed

Aisen PS. Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011; 9:101. View in: PubMed

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 3; 304(17):1903-11. View in: PubMed

Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov; 133(11):3336-48. View in: PubMed

McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010 Nov; 6(6):482-93. View in: PubMed

Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 Sep; 6(5):412-9. View in: PubMed

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010 Aug; 31(8):1340-54. View in: PubMed

Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. View in: PubMed

McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. View in: PubMed

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010 Jun; 223(2):334-46. View in: PubMed

Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. View in: PubMed

Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010 May; 6(3):239-46. View in: PubMed

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, Jagust W, Toga AW, Lee VM, Shaw LM. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 May; 6(3):230-8. View in: PubMed

Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May; 6(3):202-11. e7. View in: PubMed

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM. Therapeutics for cognitive aging. Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. View in: PubMed

Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. View in: PubMed

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010 Mar; 67(3):308-16. View in: PubMed

Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. View in: PubMed

Tractenberg RE, Fillenbaum G, Aisen PS, Liebke DE, Yumoto F, Kuchibhatla MN. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Curr Gerontol Geriatr Res. 2010; 510614. View in: PubMed

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan; 9(1):119-28. View in: PubMed

Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. View in: PubMed

Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen PS, Tariot PN, Quinn JF. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. View in: PubMed

Tractenberg RE, Aisen PS, Hancock GR, Rebeck GW. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiol Aging. 2009 Aug; 30(8):1327-8. View in: PubMed

Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. View in: PubMed

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr; 65(4):403-13. View in: PubMed

Vozdolska R, Sano M, Aisen P, Edland SD. The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009 Apr; 6(2):126-32. View in: PubMed

Aisen PS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008. " Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. View in: PubMed

Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. View in: PubMed

Aisen PS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008. " Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. View in: PubMed

Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci Lett. 2009 Jan 23; 450(1):51-5. View in: PubMed

Aisen PS. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009; 1(1):2. View in: PubMed

Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009; 16(2):235-70. View in: PubMed

Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. View in: PubMed

Tractenberg RE, Aisen PS. Agreement in cognitive and clinical assessments in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(4):344-52. View in: PubMed

Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol. 2009; 21(1):129-36. View in: PubMed

Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009; 7:7. View in: PubMed

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. View in: PubMed

Aisen PS. Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. View in: PubMed

Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen PS. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. View in: PubMed

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug; 65(8):1031-8. View in: PubMed

Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15. View in: PubMed

Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008 Jun 24; 1216:92-103. View in: PubMed

Aisen PS. Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. View in: PubMed

Aisen PS. Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. View in: PubMed

Aisen PS. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. View in: PubMed

Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. View in: PubMed

Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen PS, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett. 2008 Apr 25; 435(3):186-9. View in: PubMed

Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. View in: PubMed

Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. View in: PubMed

Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008 Feb; 5(1):73-82. View in: PubMed

Aisen PS. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. View in: PubMed

Aisen PS. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. View in: PubMed

Aisen PS. Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. View in: PubMed

Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007 Nov; 26(9):2458-68. View in: PubMed

Aisen PS. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006. "--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. View in: PubMed

Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep; 4(4):473-8. View in: PubMed

Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 2007 Feb 12; 18(3):293-6. View in: PubMed

Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007; 31(2):165-70. View in: PubMed

Tractenberg RE, Weiner MF, Aisen PS, Kaye JA, Fuh JL. A simple method to rule out dementia with temporal orientation. Alzheimers Dement. 2007 Jan; 3(1):28-32. View in: PubMed

Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006 Dec; 99(6):1555-63. View in: PubMed

Walsh SP, Raman R, Jones KB, Aisen PS. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. View in: PubMed

Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. View in: PubMed

Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. View in: PubMed

Aisen PS. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers Dement. 2006 Oct; 2(4):272-4. View in: PubMed

Aisen PS. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers Dement. 2006 Jul; 2(3):153-4. View in: PubMed

Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. View in: PubMed

Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. View in: PubMed

Aisen PS. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. View in: PubMed

Tractenberg RE, Aisen PS, Chuang YL. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. View in: PubMed

Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res. 2005 Apr; 2(2):265-8. View in: PubMed

Aisen PS. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. View in: PubMed

Tractenberg RE, Weinstein M, Weiner MF, Aisen PS, Fuh JL, Goldman N, Chuang YL. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 2005; 24(1-2):110-6. View in: PubMed

Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. View in: PubMed

Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. View in: PubMed

Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005; 11(4):353-68. View in: PubMed

Walsh S, Aisen PS. Inflammatory processes and Alzheimer's disease. Expert Rev Neurother. 2004 Sep; 4(5):793-8. View in: PubMed

Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 2; 319(3):733-7. View in: PubMed

Saunders PA, Aisen PS. Georgetown University School of Medicine. Acad Med. 2004 Jul; 79(7 Suppl):S45-50. View in: PubMed

Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. View in: PubMed

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 4; 289(21):2819-26. View in: PubMed

Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. View in: PubMed

Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. View in: PubMed

Aisen PS. Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. View in: PubMed

Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep; 1(5):279-84. View in: PubMed

Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS, Pasinetti GM. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002 May-Jun; 23(3):327-34. View in: PubMed

Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. View in: PubMed

Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. View in: PubMed

Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 2002 Feb; 103(2):157-62. View in: PubMed

Powered bySC CTSI